Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

A legfontosabb adatok

Ki végzi
BioTissue Holdings, Inc
Hol
Chapel Hill, Fort Worth, McAllen, Miami, Nashville, New Orleans, New York, North Chicago, Portland, Richmond Heights, Roanoke, San Antonio, San Francisco, St. George, Sylmar és West Palm Beach (Egyesült Államok)Mind a 16 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
220 fő vett részt
Kezdés
2020. júl. 1.
Befejezés
2024. jún. 12.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • TTAX01
  • Standard Care
A regiszteradat frissítve
2024. június 14.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • The subject has signed the informed consent form
  • The subject is male or female, at least 18 years of age inclusive at the date of Screening
  • The subject has confirmed diagnosis of Type I or Type II diabetes
  • The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot
  • The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening
  • The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule
  • The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis
  • The subject has an ABI ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg
  • The subject is under the care of a physician for the management of Diabetes Mellitus
  • The subject is willing to return for all mandatory visits as defined in the protocol
  • The subject is willing to follow the instructions of the trial Investigator

Ki nem vehet részt

  • The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening
  • The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening
  • The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™)
  • The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner)
  • The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer
  • The subject's index ulcer is primarily located on the dorsal surface of the foot
  • The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure
  • The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening
  • The subject has an allergy to primary or secondary dressing materials used in this trial
  • The subject has an allergy to glycerol
  • The subject's index ulcer is over an acute Charcot deformity
  • Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection
  • The subject has a glycated hemoglobin A1c (HbA1c) level of > 12%
  • The subject has a contralateral major amputation of the lower extremity
  • The subject is pregnant
  • The subject is a nursing mother
  • The subject is unable to sustain off-loading as defined by the protocol

Helyszínek itt: Egyesült Államok

  • University of North CarolinaChapel Hill, Egyesült Államok
  • JPSFort Worth, Egyesült Államok
  • Futuro Clinical Trials, LLCMcAllen, Egyesült Államok
  • University of MiamiMiami, Egyesült Államok
  • Vanderbilt University Medical CenterNashville, Egyesült Államok
  • Ochsner Medical CenterNew Orleans, Egyesült Államok
  • Mount Sinai WestNew York, Egyesült Államok
  • Rosalind Franklin UniversityNorth Chicago, Egyesült Államok
  • Oregon Health Science UniversityPortland, Egyesült Államok
  • University Hospitals Richmond Medical CenterRichmond Heights, Egyesült Államok
  • Carilion ClinicRoanoke, Egyesült Államok
  • Bio-X-Cell ResearchSan Antonio, Egyesült Államok
  • Center for Clinical Research Inc.San Francisco, Egyesült Államok
  • Foot & Ankle InstituteSt. George, Egyesült Államok
  • UCLA Olive ViewSylmar, Egyesült Államok
  • Paley Orthopedic & Spine InstituteWest Palm Beach, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks of initiating therapy, compared with standard care alone. This confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

A vizsgálat 2 csoportja

  • TTAX01A vizsgált kezelés

    TTAX01 plus standard care

    Kezelés: TTAX01 és Standard Care

  • ControlEgyéb csoport

    Standard Care alone

    Kezelés: Standard Care

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter Phase 3 Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
A regiszteradat frissítve
2024. június 14.